IBERE PHARMACEUTICALS - FORM S-1 - EX-99.8 - EXHIBIT 99.8 - February 8, 2021

Attached files

file filename
S-1 - FORM S-1 - IBERE PHARMACEUTICALStm215210d1_s-1.htm
EX-99.10 - EXHIBIT 99.10 - IBERE PHARMACEUTICALStm215210d1_ex99-10.htm
EX-99.9 - EXHIBIT 99.9 - IBERE PHARMACEUTICALStm215210d1_ex99-9.htm
EX-99.7 - EXHIBIT 99.7 - IBERE PHARMACEUTICALStm215210d1_ex99-7.htm
EX-99.6 - EXHIBIT 99.6 - IBERE PHARMACEUTICALStm215210d1_ex99-6.htm
EX-99.5 - EXHIBIT 99.5 - IBERE PHARMACEUTICALStm215210d1_ex99-5.htm
EX-99.4 - EXHIBIT 99.4 - IBERE PHARMACEUTICALStm215210d1_ex99-4.htm
EX-99.3 - EXHIBIT 99.3 - IBERE PHARMACEUTICALStm215210d1_ex99-3.htm
EX-99.2 - EXHIBIT 99.2 - IBERE PHARMACEUTICALStm215210d1_ex99-2.htm
EX-99.1 - EXHIBIT 99.1 - IBERE PHARMACEUTICALStm215210d1_ex99-1.htm
EX-23.1 - EXHIBIT 23.1 - IBERE PHARMACEUTICALStm215210d1_ex23-1.htm
EX-14 - EXHIBIT 14 - IBERE PHARMACEUTICALStm215210d1_ex14.htm
EX-10.8 - EXHIBIT 10.8 - IBERE PHARMACEUTICALStm215210d1_ex10-8.htm
EX-10.7 - EXHIBIT 10.7 - IBERE PHARMACEUTICALStm215210d1_ex10-7.htm
EX-10.6 - EXHIBIT 10.6 - IBERE PHARMACEUTICALStm215210d1_ex10-6.htm
EX-10.5 - EXHIBIT 10.5 - IBERE PHARMACEUTICALStm215210d1_ex10-5.htm
EX-10.4 - EXHIBIT 10.4 - IBERE PHARMACEUTICALStm215210d1_ex10-4.htm
EX-10.3 - EXHIBIT 10.3 - IBERE PHARMACEUTICALStm215210d1_ex10-3.htm
EX-10.2 - EXHIBIT 10.2 - IBERE PHARMACEUTICALStm215210d1_ex10-2.htm
EX-10.1 - EXHIBIT 10.1 - IBERE PHARMACEUTICALStm215210d1_ex10-1.htm
EX-5.2 - EXHIBIT 5.2 - IBERE PHARMACEUTICALStm215210d1_ex5-2.htm
EX-5.1 - EXHIBIT 5.1 - IBERE PHARMACEUTICALStm215210d1_ex5-1.htm
EX-4.4 - EXHIBIT 4.4 - IBERE PHARMACEUTICALStm215210d1_ex4-4.htm
EX-4.3 - EXHIBIT 4.3 - IBERE PHARMACEUTICALStm215210d1_ex4-3.htm
EX-4.2 - EXHIBIT 4.2 - IBERE PHARMACEUTICALStm215210d1_ex4-2.htm
EX-4.1 - EXHIBIT 4.1 - IBERE PHARMACEUTICALStm215210d1_ex4-1.htm
EX-3.2 - EXHIBIT 3.2 - IBERE PHARMACEUTICALStm215210d1_ex3-2.htm
EX-3.1 - EXHIBIT 3.1 - IBERE PHARMACEUTICALStm215210d1_ex3-1.htm
EX-1.1 - EXHIBIT 1.1 - IBERE PHARMACEUTICALStm215210d1_ex1-1.htm

 

Exhibit 99.8

 

Consent of Elaine V. Jones

 

In connection with the filing by Ibere Pharmaceuticals (the “Company”) of its Registration Statement (the “Registration Statement”) on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of the Company in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments and supplements thereto.

 

Dated: February 8, 2021

 

/s/ Elaine V. Jones  
Elaine V. Jones